Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Another exciting area of personalized medicine is using nanotechnology for gene therapy. Gene therapy involves altering or ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

The Moderna and Pfizer agreements include options for a total of 600 million doses, 300 million apiece, but these can only be exercised with additional funding from Congress, according to HHS.

Apart from the CDC’s restrictive recommendation, mRESVIA also faces the unenviable task of going up against incumbent RSV shots from GSK and Pfizer. Following news of Moderna’s cost-cutting ...

Today, Moderna sells just two products: its Covid vaccine called Spikevax — a rival to Comirnaty from Pfizer and BioNTech, ...

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...